Sanofi to provide manufacturing support to Johnson & Johnson for their COVID-19 vaccine to help address global supply demandshttps://www.sanofi.com/en/media-room/press-releases/2021/2021-02-22-11-40-00-2179318Sanofi has entered into an agreement with Janssen Pharmaceutical NV and Janssen Pharmaceuticals, Inc., two of the Janssen Pharmaceutical Companies of Johnson & Johnson, under which Sanofi will support manufacturing of Janssen´s COVID-19 vaccine in order to address the COVID-19 pandemic and supply needs. Janssen has submitted an application to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization for its single-dose Janssen COVID-19 vaccine candidate and an application for conditional marketing authorisation to the European Medicines Agency.
Once authorized, Sanofi will provide Johnson & Johnson access to the established infrastructure and expertise of its vaccine manufacturing plant in Marcy l’Etoile, France, to formulate and fill vials of Janssen’s COVID-19 vaccine candidate in 2021, at a rate of approximately 12 million doses per month.
Just in case anyone was worried about J & J's manufacturing capacity. More seriously, because the storage temperature for this vaccine is not as low as Pfizer's or Moderna's, worldwide demand may be higher.
